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Abstract
Background: Artemisinin-combination therapy is a highly effective treatment for uncomplicated falciparum malaria
but parasite recrudescence has been commonly reported following artemisinin (ART) monotherapy. The dormancy
recovery hypothesis has been proposed to explain this phenomenon, which is different from the slower parasite
clearance times reported as the first evidence of the development of ART resistance.
Methods: In this study, an existing P. falciparum infection model is modified to incorporate the hypothesis of
dormancy. Published in vitro data describing the characteristics of dormant parasites is used to explore whether
dormancy alone could be responsible for the high recrudescence rates observed in field studies using
monotherapy. Several treatment regimens and dormancy rates were simulated to investigate the rate of clinical
and parasitological failure following treatment.
Results: The model output indicates that following a single treatment with ART parasitological and clinical failures
occur in up to 77% and 67% of simulations, respectively. These rates rapidly decline with repeated treatment and
are sensitive to the assumed dormancy rate. The simulated parasitological and clinical treatment failure rates after 3
and 7 days of treatment are comparable to those reported from several field trials.
Conclusions: Although further studies are required to confirm dormancy in vivo, this theoretical study adds
support for the hypothesis, highlighting the potential role of this parasite sub-population in treatment failure
following monotherapy and reinforcing the importance of using ART in combination with other anti-malarials.
Background
Artemisinin-combination therapy (ACT) is the WHO
recommended treatment for uncomplicated Plasmodium
falciparum malaria [1]. It is imperative that artemisinin
(ART) is used in combination with other anti-malarials
partially because parasite recrudescence is common fol-
lowing ART monotherapy. The reported 28-day parasito-
logical failure rates of ART monotherapy vary widely,
from 2% to 50% [2,3]. This appears to be a feature of
ART monotherapy and is independent of the observation
of increased parasite clearance times which is considered
the first evidence of ART resistance in the parasite [4]. It
had been thought that because the ART class of com-
pounds have a very short half-life they cannot eliminate
all parasites during the short treatment time. However,
while the rate of parasite recrudescence generally
decreases with increasing duration of treatment, parasite
recrudescence following 5 or 7 days of treatment is still
common [3,5], and is hard to explain based on the drugs’
potency and pharmacokinetic/pharmocodynamic proper-
ties alone. Furthermore, the treatment failures observed
after ART monotherapy are not due to parasite resistance
since retreatment with the same compound is equally
effective as the initial treatment [6,7].
Another hypothesis that has been presented for the fre-
quent occurrence of recurrent infections following ART
monotherapy is that some ART-treated parasites enter a
state of quiescence, or dormancy, where they are protected
from the drugs lethal effects, but recover at a later date to
resume normal growth [8,9]. Recent in vitro studies show
that dormancy can be readily induced in P. falciparum
using dihydroartemisinin (DHA) [10] or ART itself [11].
Following exposure to 200 ng/ml (~7 × 10-7 M) DHA for
6 hours parasites recovered between 3 and 20 days post-
treatment at an overall rate between 0.044% and 0.145%,
depending on the parasite line [10]. Complete eradication
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of parasites was only achieved when a threshold concen-
tration of 3 × 10-8 M of ART was administered twice daily
for at least five days or when used in combination with
mefloquine at levels above the respective minimum inhibi-
tory concentrations (MICs) [12]. Interestingly this dor-
mancy state has also been postulated to occur following
in vitro treatment with other anti-malarial drugs such as
pyrimethamine, atovaquone and mefloquine [13-15],
although high recrudescence rates following monotherapy
with these drugs (that were not due to the selection of a
parasite subpopulation carrying resistance mutations) have
not been commonly reported. This may be due to the long
half-lives of these drugs compared to ART.
With the growing reliance on ACT, but only some
combinations available as fixed-dose treatments, the risk
of ART monotherapy is ever present so it is important
to investigate whether dormancy is induced in vivo and,
if so, the impact that it may have on the successful
treatment of patients. This study is focused on the theo-
retical question of whether dormancy could be responsi-
ble for the high recrudescence rates observed in field
studies using monotherapy, under the assumption that
the in vitro findings are applicable in vivo. The process
being modelled is not one of parasite resistance, but a
drug-induced temporary pause in the development of
some parasites.
Hoshen et al [9] have previously modelled the concept
of dormancy using a PK-PD model for 7 days following
treatment. However, the parameters used to characterize
dormancy, 0.2% of parasites becoming dormant for
18 hours, significantly under-estimate the duration of
dormancy compared to recent data [10]. Here the most
recent and comprehensive data on dormancy rates and
duration are used in an in-host stochastic simulation
model to better understand the potential impact of para-
site dormancy.
Methods
A previously published computer simulation model of
the with-in host dynamics of P. falciparum infections
was expanded to incorporate parasite dormancy [16]
(see Additional file 1). The model included three types
of human immune response which develop during an
infection, as well as antigenic variation within the para-
site. The parameter values used were those obtained
previously from fitting the model to data from malaria
naïve individuals infected with the El Limon and Santee
Cooper P. falciparum strains.
The model was used to simulate treatment using a
daily dose of ART given for 1, 3 or 7 days. The treat-
ment is initiated the day after the first occurrence of
fever (Day 1), or up to 3 days later (Days 2 to 4). This
delay in treatment was included to reflect the reported
treatment seeking behaviour of individuals where only a
small proportion of people received treatment within
24 hours of the onset of symptoms [17-19]. Since the
occurrence of fever is assumed to be associated with the
release of toxins from rupturing infected erythrocytes
(iRBC), the predominant parasite stage during the fever
is ring-stage. Therefore parasites are mature-stages
when treatment is administered on Days 1 and 3, and
ring-stages when treatment is administered on Days 2
and 4.
In order to include dormancy in the model it was
assumed that ART treatment caused a small percentage
of asexual parasites to become dormant (to later recover)
and killed the remainder. Inadequate killing of parasites
by the drug was not considered. The dormant parasites
wake at the same asexual stage, expressing the same
PfEMP1 variant, as when treatment was administered. It
was assumed the drug had a stage-specific effect with a
higher proportion of ring-stage parasites becoming dor-
mant than mature stage parasites [8,11]. The dormancy
rates and distribution of waking times for ring-stage
parasites reflected in vitro data following parasite expo-
sure to 200 ng/ml DHA [10]. For the single dose treat-
ment, the majority of the parasites were assumed to be
killed by the treatment and dormancy rates were 0.1158%
for rings and 0.050% for mature stages, with recovery to
resume active growth occurring between 4 and 17 days
post-treatment [10]. For the three-day regime the dor-
mancy rate of ring-stage parasites was assumed to be
0.0116%, 10-fold lower than the single dose treatment
[10]. Due to a lack of experimental data relating to recov-
ery after seven days of dosing two sets of simulations
were conducted; 1) using the same overall dormancy rate
as for the three-day simulation, and 2) a regime where
overall recovery was 0.0012%, or approximately 100-fold
lower than for a single dose. In all multiple dosing simu-
lations the waking profile and proportion of mature
stages becoming dormant were unchanged from the sin-
gle dose simulation, and treatment was applied when
parasites were ring-stage.
For each treatment regime considered 2,500 simula-
tions of infections in malaria naïve hosts were con-
ducted. The primary output in this study was the
proportion of simulations in which the individual failed
treatment, that is, had clinical symptoms re-develop fol-
lowing treatment, and the timing of these symptoms.
The 28-day parasitological failure rates were also
reported.
Results
Host immunity and treatment failure
The results show that there were three distinct phases in
parasite dynamics following treatment (Figure 1). The
first represented the minimum dormancy period imme-
diately following treatment when all surviving parasites
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are dormant. The second phase occurred after the para-
sites started to recover from dormancy. During this per-
iod the anti-PfEMP1 antibodies triggered prior to
treatment were able to control parasitaemia, causing a
gradual decrease in the absolute number of viable (dor-
mant or growing) parasites. The final phase was one of
renewed growth which occurred when parasites
switched to a PfEMP1 variant for which no antibodies
had been produced.
Recrudescence rate and timing following a single dose of
ART
The overall simulated clinical failure rates were 60.6%,
67.0%, 45.2% and 62.6% for treatment given 1 to 4 days
after the initial fever episode, respectively. Symptomatic
recurrence occurred at two distinct time periods: 29 to
48 days after the start of treatment and 55 to 78 days
after the start of treatment (Figure 2). The clinical fail-
ure rate during the first period varied between 4.8% (for
treatment given on Day 3) and 17.2% (for treatment
given on Day 2). The majority of failures occurred in
the later group between 55 and 78 days.
The proportion of the simulations that had a biomass
equivalent to > 50 parasites/μl at 28 days (parasitological
Figure 1 Example of simulated parasite dynamics following treatment with a single dose of ART and 0 day treatment delay. A) Within-
host parasite density over the first 50 days of infection and corresponding non-specific immune response (black bar). The coloured horizontal
bars indicate three distinct phases post-treatment: dormancy (red), recovery (yellow) and renewed growth (green). B) Presence/absence of
PfEMP1 variants that have > 10,000 parasites expressing the variant. Black: PfEMP1 variants where the corresponding anti-PfEMP1 antibodies were
triggered prior to treatment. Green: PfEMP1 variants where corresponding anti-PfEMP1 antibodies were not triggered prior to treatment (ie
density for parasites expressing variant prior to treatment did not reach the antibody threshold of 12 parasites/μl).
Figure 2 Profile of simulated clinical failures following
treatment with artemisinin for single and multiple dosing
regimes. Overall dormancy rates for ring-stage parasites were
0.1158% for single dose, 0.0116% for 3 dose and 7 dose (1), and
0.0012% for 7 dose (2).
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failures) after treatment were 58.2%, 77.2%, 28.2% and
39.5% for treatment given on Days 1 to 4, respectively.
Although patent parasitaemia was commonly seen in
the simulations at 28-days post-treatment, the majority
of these infections were suppressed below the pyrogenic
threshold by the immune system during the first
48 days, creating a difference in the parasitological and
clinical failure rates.
The impact of the waking profile on treatment failure
rates was investigated. Earlier recovery of parasites from
dormancy resulted in higher overall failure rates, earlier
presentation of failures and a larger proportion of fail-
ures occurring before 50 days.
Multiple ART dosing
The proportion of treatment failures was highly sensitive
to the dosing regimen and dormancy rate. However the
relationship between clinical failure rate and overall dor-
mancy rate was not linear. The proportion of clinical
failures decreased from 67.0% after a single ART dose
(overall dormancy rate of 0.1158%) to 37.8% after 3
doses (overall dormancy rate of 0.0116%; Figure 2). In
comparison the proportion of simulations with parasito-
logical failures (> 50 parasites/μl) at 28 days post-treat-
ment showed a larger proportional decrease from 77.2%
to 24.7% (Figure 3). When the dosing was extended to
seven days there was a slight, but not significant, reduc-
tion in clinical and parasitological failure compared to
the three-day dose when the three-dose dormancy rates
were applied (Figure 2). The clinical failure and 28-day
parasitological failure rates dropped dramatically to 5.2%
and 1.0% respectively when the dormancy rate was
decreased to 0.0012% for the 7-day treatment (Figure 3).
Discussion
In vitro data indicate that exposure to physiologically-
relevant concentrations of the ART class of drugs can
induce a period of dormancy in P. falciparum parasites
[10,11]. While this finding is yet to be confirmed
in vivo, the current modelling study was designed to
investigate the impact that dormancy alone could have
on treatment outcome. The results suggest that the dor-
mancy recovery hypothesis can explain the unusually
high treatment failure rates observed following ART
monotherapy. It should be noted that this study does
not address the issue of inadequate killing by the drug,
which is an alternate hypothesis for the observed treat-
ment failures.
Several treatment regimens were simulated: a single
dose treatment, a three-day treatment and a seven-day
treatment. Not surprisingly, the treatment failure rates
decreased with longer treatment due to the lower
assumed dormancy rate. The clinical failures were pre-
dicted to occur in two distinct groups with the propor-
tion in each group dependent on the dormancy recovery
rate; lower dormancy recovery rates were associated
with a higher proportion of late failures. This pattern
most probably reflects the interaction of the waking
parasites with the host immune system.
All of the simulated infections had some recrudescent
parasites due to waking dormant parasites. However,
only a percentage of these developed into clinical recur-
rences or a measurable parasitaemia due to the involve-
ment of the immune system. The presence of
recrudescent parasites (detected by PCR) without clini-
cal signs or symptoms was noted in a study conducted
in children in Gabon and was attributed to humoral
immunity being able to control low-level parasitemia
[20]. It is important to note that although the model
used in the current study represented malaria naïve
hosts, it does allow the development of some immunity
to the specific parasite through the duration of the
infection. It would be expected that as the host immune
response improves with repeated exposure, fewer recru-
descent infections would develop.
The predicted 28-day parasitological failure rate in the
simulated population following three days of treatment
agrees with the rates reported from several clinical trials.
In the simulated output 25% of infections had > 50
parasites/μl at day 28 compared to 29% in a Thai study
of hospitalised adults where failure was determined by
intensive microscopy [7] and 28% (PCR-corrected) in a
study in symptomatic children in Gabon [20]. This sug-
gests that the dormancy rates taken from in vitro data
following three short exposures to DHA may be repre-
sentative of the in vivo dormancy rate. In lieu of data on
the dormancy rate following repeated dosing akin to
seven days of treatment, but recognizing that dormancy
parameters are dose related [10], two different simula-
tions for seven-day treatment were conducted using
dormancy rates of 0.0116% and 0.0012%. The predicted
Figure 3 Predicted parasitological failure rates at 28 days post-
treatment for several artemisinin dosing regimes. Failure rates
for three limits of detection are displayed. Dormancy rates are as
described for Figure 2.
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28-day parasitological failure rates for these simulations
were 18.4% and 2.4%, respectively. In the Central Afri-
can Republic the 28-day PCR-corrected failure rate in
non-immune adults following a seven-day course of
artesunate treatment was 5% [21], suggesting the in vivo
dormancy recovery rate following seven-day treatment
may be close to 0.0012%.
Differences were noted in the predicted treatment fail-
ure rate when the profile of recovery changed. Although
parasite recovery was permitted for up to 17 days, in
terms of recrudescence, it is the first brood of parasites
to wake after treatment ceases which have the largest
impact. The waking profiles used in this study did not
allow parasites to start to recover until three days after
treatment. It is possible that parasites recover earlier
than this but this is expected to have minimal impact
on the model results since these parasites would be re-
exposed to the drug during this period due to multiple
dosing regimes.
The timing of treatment also impacted on the pre-
dicted treatment failure rates. There were differences
between treatments on odd or even days, a result related
to whether the parasites were treated at ring-stage or
mature stages. Although not well tested, there are preli-
minary laboratory data [11](Kyle, unpublished data) and
modelling [22] which indicates that mature-stage para-
sites are more sensitive to ART, leading to the assump-
tion of a lower dormancy rate for mature parasites.
Hence, a single dose applied to mature stage parasites in
the model produced lower failure rates than a single
dose administered to ring-stage parasites. However,
further laboratory studies are required to better under-
stand the effect of ART on mature stage parasites, parti-
cularly the effect of multiple dosing.
This study has demonstrated that inclusion of ART-
induced dormancy in a within-host simulation model of
P. falciparum can generate treatment failures, and that
the predicted proportion of treated hosts with detectable
parasites 28 days after treatment is generally comparable
to those measured in ART monotherapy field trials.
Further clinical investigations are required to confirm the
occurrence of dormancy in vivo, but this theoretical
study adds support for the dormancy recovery hypoth-
esis, and highlights the potential role this parasite sub-
population may have in treatment failure. When
deployed in ACT, the impact of the dormant population
on efficacy is likely reduced by the companion drug low-
ering the dormancy rate [10] and, in the case of long-act-
ing companions, mopping up the waking parasites. A
better understanding of the dormancy recovery process
and the impact that companion drugs have on dormant
and recovered parasites will help establish treatment
combinations and regimes that minimize the possibility
of dormant parasites surviving to cause treatment failure.
This improved understanding of ART-induced dormancy
needs to occur in parallel to the efforts being made to
understand and contain the development of ART resis-
tance since these focus on different, but important,
aspects of the parasites response to ART; dormancy is
proposed to be an inherent parasite response following
exposure to ART, while resistance involves adaptation or
changes of the parasite’s response to ART, particularly
the susceptibility of ring-stage parasites [22].
Conclusions
Artemisinin induced dormancy provides one plausible
explanation for the high level of recrudescence reported in
the field following monotherapy. Although repeated treat-
ment reduced the dormancy recovery rate and the rate of
recrudescence, a small proportion of failures were still pre-
dicted. The findings highlight the importance of using
artemisinin in combination with other anti-malarial drugs
and using the combinations as fixed-dose treatment.
Additional material
Additional file 1: Details of within-host model of P. falciparum
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